The Stem Cell Institute of America Case: How a $5.15 Million Judgment Was Built

In January 2025, the Federal Trade Commission and the Georgia Attorney General’s Office announced a pair of federal court orders against the founders of the Stem Cell Institute of America and several related companies. The defendants were permanently banned from marketing regenerative medicine treatments and ordered to pay $5,155,146. It is one of the most useful cases a clinic owner can study, because almost everything people repeat about it is slightly wrong.

This was not a settlement, and it did not trace back to a single Instagram post. It was a litigated judgment that followed years of marketing and a full summary-judgment ruling. The full record is on the FTC case page (matter 182-3125). Below is what the case actually involved and the parts worth carrying into your own practice.

What the operation actually was

The case is captioned Federal Trade Commission and State of Georgia v. Steven D. Peyroux, Brent J. Detelich, et al., filed in 2021 in the U.S. District Court for the Northern District of Georgia (No. 1:21-cv-03329-AT). The defendants included two individuals, Steven Peyroux and Brent Detelich, and three companies: Regenerative Medicine Institute of America, LLC, doing business as Stem Cell Institute of America (SCIA); Physicians Business Solutions, LLC; and Superior Healthcare, LLC.

According to the court record, Peyroux (a chiropractor) and Detelich (a former chiropractor) founded SCIA in 2015. SCIA did not primarily treat patients. It trained other clinics. SCIA taught chiropractors and other practitioners how to market unproven stem cell therapy, how to recruit patients through advertising, how to host free “educational seminars,” and how to run the consultations that followed. It gave client clinics access to a “vault” of sample advertisements and the appearance of belonging to a national network.

The same machine fed the founders’ own clinic, Superior Healthcare, which charged up to $5,000 per stem cell injection, with many patients receiving more than one. The court record describes a targeted funnel: Facebook ads led to seminar sign-ups, sign-ups led to a run of “drip” emails and a brochure, and the seminars were built to overcome objections and close the sale. The buyers were almost entirely elderly and disabled people.

What the court found

In March 2024, the court granted summary judgment for the FTC and the State of Georgia on all counts. The findings are specific and worth reading closely, because they map directly onto how ordinary clinics get into trouble.

• Disease and superiority claims.The defendants claimed stem cell therapy cures, treats, or mitigates orthopedic conditions, including osteoarthritis, neuropathy, plantar fasciitis, and joint pain, and that it was comparable or superior to surgery, steroid injections, and painkillers. The clinic website went further, suggesting the therapy could address conditions like Alzheimer’s, Parkinson’s, multiple sclerosis, and COPD. None of it was substantiated.
• False “approved” claims.The defendants represented that their regenerative medicine compliance program was approved by the FTC and the FDA. It was not. Neither agency “approves” a marketing or compliance program.
• Arming other clinics.The court held the defendants liable for supplying client clinics with false and unsubstantiated advertising materials and training. The claims did not have to be made on the defendants’ own page to count.

That last point is the one most people miss. If you license a marketing “vault,” buy a done-for-you funnel, or run a vendor’s seminar deck, those claims become your claims the moment they appear on your surface. The specific phrases that draw this scrutiny are catalogued in our breakdown of the stem cell marketing phrases that cost clinics the most, and the line between a permitted structure/function statement and a prohibited disease claim is covered in structure/function versus disease claims.

Why the money is state law, not an FTC settlement

The $5,155,146 is frequently described as an “FTC settlement.” Both halves of that phrase are inaccurate, and the reason matters.

First, it was not a settlement. The defendants litigated and lost on summary judgment. The court then held a hearing on the scope of relief and issued its own orders on December 26, 2024.

Second, the money did not come from the FTC’s own authority. In AMG Capital Management v. FTC (2021), the Supreme Court held that Section 13(b) of the FTC Act does not authorize the FTC to obtain monetary relief. So the dollars here rest entirely on Georgia state law. The State of Georgia sought restitution and civil penalties under the Georgia Fair Business Practices Act, and the court awarded both:

• $3,310,146 in restitution from Peyroux and Detelich, to refund the consumers who paid for the injections.
• $1,845,000 in civil penalties from Peyroux, Detelich, and Physicians Business Solutions.

The penalty figure is itself a lesson in how surfaces stack. The court treated each separate dissemination as a violation and priced them by seriousness: a lower amount for each of the 1,330 days the website was posted, higher amounts for each of the 59 Facebook ad campaigns and the 161 brochure downloads, and the highest for each of the 148 seminars. For a deeper walk-through of how regulators count each surface separately, see how one public claim can pull an entire marketing surface into scope.

The ban, and the part the court refused

The injunctive order is permanent. The defendants are barred for life from advertising, marketing, promoting, offering for sale, or selling any regenerative medicine treatment, a category the order defines to include stem cell therapy, amniotic and umbilical-cord products, and exosomes. They are also barred from telling anyone that a compliance program is FTC- or FDA-approved, and from handing others the means to make false claims about these treatments. Both founders are named personally, so reorganizing or selling a company does not lift the order.

One detail is worth holding onto, because it pushes back on a myth that circulated about this case. The plaintiffs asked for a 20-year compliance-reporting and order-distribution period. The court declined. It found 20 years “overly punitive” and set the reporting period at 7 years instead, while keeping the marketing ban itself permanent and reserving the right to extend the reporting window if the defendants do not comply.

The lifetime consequence here is not the reporting paperwork. It is the permanent ban on the language that made the business run. For a clinic whose revenue depends on claiming results it cannot prove, that is the whole business.

Why a clinic of any size should care

It is tempting to read this as a story about bad actors who deserved it and move on. The more useful reading is structural. Courts have repeatedly treated processed stem cell products as drugs and biologics subject to FDA oversight, not as ordinary medical services; our writeup of United States v. Regenerative Sciences covers that line. On top of the FDA question sits the advertising question, and the advertising question is where most clinics are actually exposed.

Notice what did not protect the defendants. They were not a national pharmaceutical company. Two of the three corporate defendants had already been through bankruptcy. The conduct still drew the full weight of a federal agency working alongside a state attorney general, personal liability for the owners, and a permanent ban. Size was not a shield, and neither was the fact that much of the worst content lived in materials handed to other clinics rather than on a polished home page.

What to take into your own practice

1. Treat every surface as evidence. Website, archived pages, social posts, paid ads, seminar decks, and brochures all count, and old content does not grandfather in. Inventory what is publicly reachable before a regulator does it for you.
2. Own the claims in anything you license.A vendor’s “compliant” ad vault is not compliant because the vendor says so. Once it is on your channel, it is your representation. Read it the way an investigator would.
3. Never claim FTC or FDA approval of a program.Neither agency approves marketing, training, or compliance programs. Drop the word “approved” unless you can point to an actual product approval or clearance.
4. Write to the structure/function line, not past it.Describe what a treatment is and how patients have experienced it, without promising it cures, treats, or beats a named alternative.

The practical version

The defendants in this case did not get caught by one mistake. They got caught by a marketing system that produced the same unsupported claims across every channel for years. The defense is the mirror image: a consistent pre-publish review on every surface, so the disease claim, the guarantee, and the false approval line never reach the public in the first place. Run a free scan to see what your own pages, posts, and ads would surface under that lens.